United States-based Catabasis Pharmaceuticals is restructuring its resources to focus on late-stage lead program, Edasalonexent, intended for the treatment of Duchenne muscular dystrophy (DMD), it was reported yesterday.
The company is prioritising this program to deliver against its goal of bringing a life changing therapy to those affected by DMD.
The restructuring will reduce the firm's workforce by around 42%. As a result of the program focusing and corresponding workforce restructuring, which is expected to be completed in the second quarter of 2018, the company estimates annualised savings of around USD3.3m in personnel-related costs, with estimated one-time severance and related costs of approximately USD1m in the second quarter of 2018.
In the Phase 2 MoveDMD trial and open-label extension, edasalonexent has demonstrated consistent and sustained slowing of disease progression in boys with DMD through more than a year of treatment compared to the off-treatment control period.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study